A recent review mapped advances in CAR‑T and CAR‑NK cell therapies for acute myeloid leukemia, emphasizing engineered cell approaches that target AML antigens while mitigating myeloablation and off‑tumor toxicity. Authors summarized clinical signals from early‑phase trials, discussed antigen selection and manufacturing hurdles, and noted the potential of NK platforms to offer 'off‑the‑shelf' advantages. The review underlines that improved cell persistence, target specificity and combinatorial engineering will determine whether CAR‑based immunotherapies can become standard options for AML.